• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

    3/12/25 5:08:00 PM ET
    $ARMP
    $INVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARMP alert in real time by email

    Proceeds to be used to continue to advance development of Armata's phage product candidates

    LOS ANGELES, March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the Company at closing are $10 million before deducting transaction-related expenses.

    Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)

    Proceeds from the new financing transaction will be used to advance the Company's lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.

    "Innoviva continues to be an instrumental partner to Armata in support of our mission, the clinical development of our two lead phage cocktails, AP-PA02 and AP-SA02, and our committed team," stated Dr. Deborah Birx, Chief Executive Officer of Armata. "This financing will enable Armata to readout its Phase 1b/2a trial in acute Staphylococcus aureus bacteremia, which represents the first clinical trial for AP-SA02, and to prepare the Company for an end-of-Phase 2 meeting with the FDA in support of further clinical inquiry including a potential pivotal trial. I would like to thank the Innoviva team for their continued support. We are continuing to pursue additional sources of funding, including non-dilutive sources, to support our late-stage clinical trials."

    The secured credit agreement provides for a secured term loan facility in an aggregate amount of $10 million at an interest rate of 14.0% per annum with a maturity date of March 12, 2026.

    The Company and Innoviva also entered into amendments to the three credit and security agreements previously entered into, in order to, among other things, extend the maturity dates under such agreements to March 12, 2026.

    About Armata Pharmaceuticals, Inc.

    Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization. 

    Forward Looking Statements

    This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the SEC, including in Armata's Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and in its subsequent filings with the SEC.

    Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

    Media Contacts:

    At Armata:

    Pierre Kyme

    Armata Pharmaceuticals, Inc.

    [email protected]

    310-665-2928 x234

    Investor Relations:

    Joyce Allaire

    LifeSci Advisors, LLC

    [email protected]

    212-915-2569

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-10-million-secured-credit-agreement-with-innoviva-302400391.html

    SOURCE Armata Pharmaceuticals, Inc.

    Get the next $ARMP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ARMP
    $INVA

    CompanyDatePrice TargetRatingAnalyst
    Innoviva Inc.
    $INVA
    3/7/2025$55.00Sector Outperform
    Scotiabank
    Innoviva Inc.
    $INVA
    6/18/2024Overweight
    Cantor Fitzgerald
    Innoviva Inc.
    $INVA
    7/20/2022$16.00Neutral
    Goldman
    Innoviva Inc.
    $INVA
    2/23/2022$10.00 → $12.00Underweight
    Morgan Stanley
    Innoviva Inc.
    $INVA
    2/11/2022$28.00Buy
    EF Hutton
    More analyst ratings

    $ARMP
    $INVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

      LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata's Corporate Controller, Richard Rychlik, will retain the position of Controller. "We are delighted to welcome David to the Armata t

      8/15/24 4:45:00 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Innoviva Appoints Stephen Basso as Chief Financial Officer

      Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind

      8/25/23 4:52:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

      LOS ANGELES, Aug. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE:ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2023, and provided a corporate update.   Second Quarter 2023 and Recent Developments: Announced leadership transition whereby world‐renowned healthcare leader and former Innoviva Board member Dr. Deborah L. Birx has been appointed Armata's new Chi

      8/14/23 7:00:00 AM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARMP
    $INVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Zhen Marianne covered exercise/tax liability with 992 shares, decreasing direct ownership by 2% to 50,320 units (SEC Form 4)

      4 - Innoviva, Inc. (0001080014) (Issuer)

      5/22/25 4:15:51 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Basso Stephen was granted 1,353 shares and covered exercise/tax liability with 237 shares, increasing direct ownership by 5% to 23,518 units (SEC Form 4)

      4 - Innoviva, Inc. (0001080014) (Issuer)

      5/22/25 4:15:16 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Small Derek A was granted 12,077 shares, increasing direct ownership by 52% to 35,249 units (SEC Form 4)

      4 - Innoviva, Inc. (0001080014) (Issuer)

      5/21/25 9:36:44 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARMP
    $INVA
    SEC Filings

    See more
    • Armata Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

      6/13/25 4:05:24 PM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Innoviva Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Innoviva, Inc. (0001080014) (Filer)

      5/21/25 4:15:25 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Armata Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)

      5/19/25 7:06:04 AM ET
      $ARMP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARMP
    $INVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Innoviva with a new price target

      Scotiabank initiated coverage of Innoviva with a rating of Sector Outperform and set a new price target of $55.00

      3/7/25 8:19:43 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Innoviva

      Cantor Fitzgerald initiated coverage of Innoviva with a rating of Overweight

      6/18/24 7:43:03 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Innoviva with a new price target

      Goldman initiated coverage of Innoviva with a rating of Neutral and set a new price target of $16.00

      7/20/22 7:30:02 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARMP
    $INVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

      FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ:INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adult

      6/12/25 7:00:00 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

      In laboratory studies, zoliflodacin has been shown to be active against Neisseria gonorrhoeae including multidrug-resistant strains. If approved, zoliflodacin could become the first new antibiotic treatment for gonorrhea in decades. Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ:INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric pat

      6/10/25 6:00:00 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva to Participate in Upcoming Investor Conferences

      Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Format: Fireside chat Date: Monday, June 9, 2025 Time: 1:20 p.m. Eastern Time Scotiabank Third Annual Healthcare Canadian Investor Day Format: 1x1 meetings Date: Tuesday, June 17, 2025 A live webcast of the fireside chat from the Gold

      6/3/25 7:00:00 AM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARMP
    $INVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

      SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)

      11/14/24 4:17:40 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Innoviva Inc.

      SC 13G - Innoviva, Inc. (0001080014) (Subject)

      5/13/24 1:58:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Innoviva Inc.

      SC 13D - Innoviva, Inc. (0001080014) (Subject)

      5/8/24 3:38:11 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARMP
    $INVA
    Financials

    Live finance-specific insights

    See more
    • Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

      Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of $26.4 million for the first quarter, reflecting 52% year-over-year growth Continued momentum across therapeutics platform with regulatory submissions for zoliflodacin and commercial launch of ZEVTERA® (ceftobiprole) progressing as planned Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today rep

      5/7/25 4:05:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

      Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 million for the full year Innoviva Specialty Therapeutics achieved U.S. net product sales of $24.9 million for the fourth quarter and $80.9 million for the full year, reflecting 47% year-over-year growth Therapeutics platform strengthened with acquisition of exclusive U.S. commercialization and distribution rights to ZEVTERA® (ceftobiprole), launching mid-2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeuti

      2/26/25 4:04:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

      Core royalty platform continued strong performance, receiving GSK royalties of $60.5 million with 6% year-over-year growth Innoviva Specialty Therapeutics' (IST) marketed portfolio achieved U.S. net product sales of $19.7 million, reflecting 68% year-over-year growth Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements. "For the

      11/6/24 4:05:00 PM ET
      $INVA
      Biotechnology: Pharmaceutical Preparations
      Health Care